Bagher AM - Search Results

1

Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM. Laprairie RB, et al. Among authors: bagher am. J Biol Chem. 2014 Sep 5;289(36):24845-62. doi: 10.1074/jbc.M114.557025. Epub 2014 Jul 18. J Biol Chem. 2014. PMID: 25037227 Free PMC article.

2

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Laprairie RB, et al. Among authors: bagher am. Br J Pharmacol. 2015 Oct;172(20):4790-805. doi: 10.1111/bph.13250. Epub 2015 Oct 13. Br J Pharmacol. 2015. PMID: 26218440 Free PMC article.

3

Co-expression of the human cannabinoid receptor coding region splice variants (hCB₁) affects the function of hCB₁ receptor complexes.

Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. Bagher AM, et al. Eur J Pharmacol. 2013 Dec 5;721(1-3):341-54. doi: 10.1016/j.ejphar.2013.09.002. Epub 2013 Oct 1. Eur J Pharmacol. 2013. PMID: 24091169

4

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Laprairie RB, et al. Among authors: bagher am. Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980. Epub 2015 Dec 23. Mol Pharmacol. 2016. PMID: 26700564

5

Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.

Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. Bagher AM, et al. Mol Pharmacol. 2016 Jun;89(6):652-66. doi: 10.1124/mol.116.103465. Epub 2016 Apr 6. Mol Pharmacol. 2016. PMID: 27053685

6

Cannabinoid receptor ligand bias: implications in the central nervous system.

Laprairie RB, Bagher AM, Denovan-Wright EM. Laprairie RB, et al. Among authors: bagher am. Curr Opin Pharmacol. 2017 Feb;32:32-43. doi: 10.1016/j.coph.2016.10.005. Epub 2016 Nov 9. Curr Opin Pharmacol. 2017. PMID: 27835801 Review.

7

Bidirectional allosteric interactions between cannabinoid receptor 1 (CB₁) and dopamine receptor 2 long (D_2L) heterotetramers.

Bagher AM, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. Bagher AM, et al. Eur J Pharmacol. 2017 Oct 15;813:66-83. doi: 10.1016/j.ejphar.2017.07.034. Epub 2017 Jul 19. Eur J Pharmacol. 2017. PMID: 28734930

8

Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.

Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM. Bagher AM, et al. Methods Mol Biol. 2018;1780:549-571. doi: 10.1007/978-1-4939-7825-0_25. Methods Mol Biol. 2018. PMID: 29856035

9

Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM. Laprairie RB, et al. Among authors: bagher am. Neuropharmacology. 2019 Jun;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. Epub 2019 Mar 30. Neuropharmacology. 2019. PMID: 30940536 Free PMC article.

10

Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.

Bagher AM, Young AP, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. Bagher AM, et al. J Neurosci Res. 2020 Dec;98(12):2496-2509. doi: 10.1002/jnr.24716. Epub 2020 Sep 2. J Neurosci Res. 2020. PMID: 32881145

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters